A small molecule agent PSMA-617 specifically attaches to prostate-specific membrane antigen on cancer cells, allowing for early detection of secondary tumors and monitoring response to therapy. This agent has shown promising results in PET scans and holds potential as a therapeutic option for hormone-resistant prostate carcinoma.
Researchers have confirmed that eosinophils release special agents attracting immune system's professional killers into cancer tissue, leading to improved cancer rejection and increased survival rates in mice. Eosinophils also normalize blood vessels in the tumor, contributing to tumor rejection.
A team of scientists has identified an enzyme called Kit, which plays a key role in the development of obesity and metabolic disorders. In mice with functioning Kit, fed a high-fat diet, obesity and insulin resistance were prevented.
Researchers found that inflammatory cells from the bloodstream play a key role in neurodegeneration in Parkinson's disease. CD95L-bearing immune cells cause damage to neurons, and blocking this molecule can prevent neurodegeneration in mice. This suggests that early treatment with drugs targeting CD95L might mitigate Parkinson's symptoms.
Researchers discovered a molecular cause for parvovirus selectivity in cancer cells, revealing the PKCη/Rdx-driven phosphorylation of PDK1. This biomarker predicts therapy effectiveness and identifies cancer cells independent of growth factors.
Researchers have discovered a nanobody called Nano-85 that can bind to intact norovirus-like particles, detecting virus in one-third of stool samples. This finding could lead to the development of an antiviral therapy for norovirus infections, particularly beneficial for immunosuppressed individuals.
A new molecule, endosialin, on hepatic stellate cells drives liver fibrosis by activating these cells. However, its absence improved the regenerative capacity of remaining liver cells without proliferating them. This finding helps understand how liver fibrosis develops and may lead to treatments for other diseases.
A new test, PLA test, evaluates the effectiveness of cancer vaccines by detecting tumor antigens presented on MHC molecules. The test has shown promising results in identifying glioma tumors and melanoma cells with specific antigens.
A study reveals that hematopoietic stem cells are vulnerable to DNA damage when rapidly dividing under stress conditions. This can lead to premature aging and increase the risk of cancer.
Researchers have developed a revolutionary model to study hematopoiesis in living organisms, revealing that at least one-third of blood stem cells produce differentiated progenitor cells. The study also shows that mature blood cells are supplied by first progenitor cells that regenerate themselves over time.
Researchers found high TNF alpha levels in tumor tissue correlate with increased numbers of activated killer cells and a favorable course of the disease. The study suggests that TNF alpha could serve as an independent biomarker for disease prognosis.
Researchers found that endothelial cells, the cells lining blood vessels, play a more active role in tumor growth than previously thought. A combination therapy involving anti-Angiopoietin-2 and metronomic chemotherapy showed promising results in reducing metastatic growth and improving survival rates in mice.
Scientists have discovered that hydrogen peroxide is a key regulator of cellular functions, transmitting signals by oxidizing specific proteins. This discovery challenges previous assumptions and opens new avenues for understanding cancer development and progression.
A team of researchers has developed a mathematical model for epigenetic silencing, which reveals how DNA sequences are silenced in cancer cells. The model explains how histone and DNA methylation work together to regulate gene expression, and could lead to new strategies for preventing cancer development.
Researchers have developed a therapeutic vaccine targeting mutant IDH1, a common genetic mutation in brain tumors. The vaccine was tested on mice and showed promising results, with immune cells recognizing and attacking cancer cells. A clinical trial is planned to test the safety of the vaccine in human patients.
Researchers discovered that cancer-causing genes are transcribed in childhood brain tumor cells due to 'hijacked' gene enhancers. The study also found that epigenetic regulation plays a crucial role in the activation of these genes, providing new targets for treatment development.
Researchers found hypermutation of inactive X chromosome is a common event in cancer, especially in rapidly growing tumors. This phenomenon affects only the inactive copy of the X chromosome and contributes to carcinogenesis.
Researchers have found a synergistic combination of valproic acid and oncolytic parvovirus H-1PV that can effectively treat cervical and pancreatic carcinomas by activating virus-induced cell death and killing cancer cells. This new therapy has the potential to arrest tumor growth in severe cases of cancer.